Dr. Feldman’s research focuses on defining the role of the transcription factor IRF4 in T-cell lymphomas (TCLs), aggressive cancers that are fatal in the majority of patients.  He proposes that IRF4 represents a rational therapeutic target for TCLs and aims to develop new strategies to block IRF4 in lymphoma cells.  Novel targeted therapies for TCL could greatly improve the outcome for patients with this disease.

 

---

Project Title: "Investigation of IRF4 as a therapeutic target in T-cell lymphomas"

Institution: Mayo Clinic

Sponsor(s) / Mentor(s): Stephen M. Ansell, MD, PhD, and Ahmet Dogan, MD, PhD

Cancer Type: Lymphomas

Research Area: Signal Transduction